Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra™ valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management. It’s an excellent choice for cardiac surgeons and their patients seeking an aortic valve solution that can be fit for the future, right from the start..

医疗保健技术的全球领导者美敦力公司今天宣布推出其在心脏外科领域的最新创新产品Avalus Ultra™瓣膜。这种下一代外科主动脉组织瓣旨在促进植入和终身患者管理的易用性。对于心脏外科医生及其寻求适合未来的主动脉瓣解决方案的患者来说，这是一个很好的选择。。

The Avalus Ultra valve is engineered for ease of implant, clear visibility for future valve-in-valve procedures, and straightforward sizing. More specifically, the Avalus Ultra surgical valve has:

Avalus Ultra瓣膜的设计旨在易于植入，为未来的瓣中瓣手术提供清晰的可视性，并且尺寸简单明了。更具体地说，Avalus Ultra手术阀具有：

A low valve profile designed to facilitate ease of use at implant.1,2

一种低瓣膜轮廓，旨在促进植入物的易用性。1,2

A polyetheretherketone (PEEK) base frame, which provides consistent circularity3, 4

聚醚醚酮（PEEK）基架，可提供一致的圆度3、4

An industry-leading Effective Orifice Area (EOA) that may allow for greater blood flow that is supported by the clinical evidence of the Avalus™ valve 5,6

行业领先的有效孔口面积（EOA），可以允许更大的血流，这是由Avalus™阀5,6的临床证据支持的

A radiopaque coil for clear visibility for future valve-in-valve procedures 7,8

一个不透射线的线圈，可以清晰地看到未来的阀中阀程序7,8

Additionally, the Avalus Ultra valve builds on 10 years of clinical experience and the long-term durability of the Avalus valve.9,10,11

此外，Avalus Ultra瓣膜建立在10年的临床经验和Avalus瓣膜的长期耐久性的基础上。9,10,11

“Patients with aortic stenosis are experiencing more complex disease, and therefore, procedures need to evolve to optimize their surgical care,” said Professor Pieter Kappetein, vice president and chief medical officer of the Cardiac Surgery, Structural Heart, and Mechanical Circulatory Support businesses in the Medtronic Cardiovascular portfolio.

美敦力心血管投资组合心脏外科、结构性心脏和机械循环支持业务副总裁兼首席医疗官PieterKappetin教授表示：“主动脉瓣狭窄患者正在经历更复杂的疾病，因此，需要改进手术程序以优化其手术护理。”。

“Rooted in this evolving need, surgeons are demanding innovative technologies like the Avalus Ultra valve that is designed for increased ease of use and long-term durability to serve patients over their lifetime.”.

“植根于这种不断发展的需求，外科医生正在要求创新技术，如Avalus Ultra瓣膜，该瓣膜旨在提高易用性和长期耐用性，以在患者的一生中为患者服务。”。

Aortic stenosis is a common heart problem typically caused by a narrowing of the heart’s aortic valve due to excessive calcium deposited on the valve leaflets. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this causes the heart to weaken and function poorly, which may lead to heart failure and increased risk for sudden cardiac death..

主动脉瓣狭窄是一种常见的心脏问题，通常是由于瓣膜小叶上沉积了过量的钙而导致心脏主动脉瓣变窄引起的。当瓣膜变窄时，它不能正确打开或关闭，使心脏更难将血液泵送到全身。最终，这会导致心脏虚弱和功能不佳，这可能导致心力衰竭并增加心源性猝死的风险。。

A treatment for patients with aortic valve disease is surgical aortic valve replacement (SAVR). During this procedure, a surgeon will make an incision in the sternum to open the chest and expose the heart. The diseased native valve is then removed, and a new artificial valve inserted. Once in place, the device is sewn into the aorta and takes over the original valve’s function to enable oxygen-rich blood to flow efficiently out of the heart..

主动脉瓣疾病患者的治疗方法是外科主动脉瓣置换术（SAVR）。在这个过程中，外科医生将在胸骨上切开，打开胸部并暴露心脏。然后移除患病的天然瓣膜，并插入新的人工瓣膜。一旦安装到位，该装置将被缝合到主动脉中，并接管原始瓣膜的功能，使富含氧气的血液能够有效地流出心脏。。

“Cardiac surgeons are looking to industry to partner with them to deliver improved innovation to treat their patients efficiently and effectively,” said Karim Bandali, Ph.D., president of the Cardiac Surgery business in the Medtronic Cardiovascular portfolio. “The Avalus Ultra valve builds on several successful innovation launches this year, including the acquisition and launch of the Penditure™ LAA Exclusion System.  Aligned our Mission, Medtronic is committed to making the investments needed to advance and deliver innovative, lifesaving devices for better lifetime patient management.”.

美敦力心血管投资组合心脏外科业务总裁卡里姆·班达利博士说：“心脏外科医生正在寻求业界与他们合作，以提供改进的创新，从而有效地治疗患者。”。“Avalus Ultra valve以今年几次成功的创新发布为基础，包括Penditure™LAA排除系统的收购和发布。美敦力秉承我们的使命，致力于进行必要的投资，以推进和提供创新的救生设备，从而更好地管理患者的一生。”。

The Avalus Ultra valve received FDA approval in January 2024 and is currently only commercially available in the United States.

Avalus Ultra阀门于2024年1月获得FDA批准，目前仅在美国上市。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。总部位于爱尔兰都柏林的美敦力公司（Medtronic plc）是全球领先的医疗保健技术公司，通过寻找和寻找解决方案，大胆应对人类面临的最具挑战性的健康问题。我们的使命是减轻痛苦，恢复健康，延长寿命，我们团结了150多个国家的95000多名充满激情的全球团队。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们丰富的知识、永不满足的好奇心以及帮助所有需要帮助的人的愿望，我们提供了创新技术，每秒钟、每小时、每天都在改变两个人的生活。